CTOs on the Move

BioVentrix

www.bioventrix.com

 
BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.bioventrix.com
  • 12647 Alcosta Boulevard Suite 400
    San Ramon, CA USA 94583
  • Phone: 925.830.1000

Executives

Name Title Contact Details

Funding

BioVentrix raised $21.7M on 05/01/2019

Similar Companies

eCardio Diagnostics

With deep roots in ambulatory monitoring technology, eCardio Diagnostics was formed to simplify and streamline the processes of cardiac event monitoring.

Digirad Corporation

Digirad Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Packaging Corp

Medical Packaging Corp is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VALUTEK

VALUTEK is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurolens

Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.